Kinross Q1 Adjusted Profit Up Slightly Despite Lower Output
Kinross Gold Corp. (TSX: K, NYSE: KGC) late Tuesday reported slightly higher adjusted first-quarter earnings than in the same period a year ago even though output was lower, helped when revenues were boosted by a higher gold price.
Read moreGold Near Steady In Quieter, 2-Sided Trading Session
Gold prices were ending a lackluster U.S. day session near steady levels after hitting a three-week low in earlier trading Tuesday.
Read moreGold Could See Strong Momentum When VIX Moves Off 10-Year Low
(Kitco News) – Investor complacency is at an all-time high as market volatility hovers around the lowest levels seen in more than a decade, according to some analysts.
Read moreAlacer Gold Posts Profit In First Quarter
Alacer Gold Corp. (TSX: ASR; ASX: AQG), which has an 80% interest in the Çöpler Gold Mine in Turkey, lists a first-quarter net profit of $8.7 million, or 3 cents per share.
Guyana Goldfields Reports Rise In 1Q Net Income
Guyana Goldfields Inc. (TSX: GUY) reports net earnings for the first quarter of $9.9 million, or 6 cents per share.
Read moreCenterra Gold’s 1Q Earnings Triple From Year Ago
Centerra Gold Inc. (TSX: CG) announces net earnings of $57 million, or 20 cents per share, on revenues of $285.3 million in the first quarter.
Read moreFXTM’s Otunuga: Gold Decline Below Support Could Entice Further Selling
Gold’s decline through technical-chart support at $1,260 an ounce could open the gate to more weakness, says FXTM Research Analyst Lukman Otunuga.
Gold Slightly Down, At 3-Week Low; New Inputs Awaited
Gold prices are slightly weaker and dropped to a three-week low in early U.S. trading Tuesday.
Read moreCenterra Gold’s 1Q Earnings Triple From Year Ago
Centerra Gold Inc. (TSX: CG) announces net earnings of $57 million, or 20 cents per share, on revenues of $285.3 million in the first quarter.
Read morePfizer reports Q1 profit beat, revenue miss
Pfizer Inc. PFE, -1.04% reported a first-quarter profit beat and revenue miss early Tuesday. Earnings for the latest quarter rose to $3.12 billion, or 51 cents per share, from $3.04 billion, or 49 cents per share, in the year-earlier period. Adjusted earnings-per-share were 69 cents, compared with the FactSet consensus of 67 cents. Revenue rose to $12.78 billion from $13.01 billion, compared with the FactSet consensus of $13.09 billion. Pfizer said its latest results were affected by one less U.S. selling day and two fewer international selling days, compared to the year-earlier period. The latest results include some legacy operations from Hospira Infusion Systems, which Pfizer completed the sale of to ICU Medical ICUI, +0.91% in early February. Pfizer shares have surged 6.5% over the last three months, compared with a 4.7% rise in the S&P 500 SPX, +0.17%